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Deregulation of TLR4 signaling 
pathway characterizes Bicuspid 
Aortic valve syndrome
Carmela R. Balistreri  1, Antonino G. M. Marullo2, Michele Madonna3, elena cavarretta2,4, 
Alberto Allegra5, Valeriana cesarini6, Alessandra iaccarino2,7, Sonia Schiavon2, 
Mariangela peruzzi2,4, Ernesto Greco8, Sebastiano Sciarretta2,3, calogera Pisano9, 
Giovanni Ruvolo9, Michele torella10 & Giacomo frati2,3
Bicuspid aortic valve (BAV) disease is recognized to be a syndrome with a complex and multifaceted 
pathophysiology. Its progression is modulated by diverse evolutionary conserved pathways, such 
as Notch-1 pathway. Emerging evidence is also highlighting the key role of TLR4 signaling pathway 
in the aortic valve pathologies and their related complications, such as sporadic ascending aorta 
aneurysms (AAA). Consistent with these observations, we aimed to evaluate the role of TLR4 pathway 
in both BAV disease and its common complication, such as AAA. To this aim, 70 subjects with BAV 
(M/F 50/20; mean age: 58.8 ± 14.8 years) and 70 subjects with tricuspid aortic valve (TAV) (M/F 35/35; 
mean age: 69.1 ± 12.8 years), with and without AAA were enrolled. Plasma assessment, tissue and 
gene expression evaluations were performed. Consistent with data obtained in the previous study on 
immune clonotypic T and B altered responses, we found reduced levels of systemic TNF-α, IL-1, IL-6, 
IL-17 cytokines in BAV cases, either in the presence or absence of AAA, than TAV cases (p < 0.0001 by 
ANOVA test). Interestingly, we also detected reduced levels of s-TLR4 in BAV cases with or without 
AAA in comparison to the two groups of TAV subjects (p < 0.0001 by ANOVA test). These results may 
suggest a deregulation in the activity or in the expression of TLR4 signaling pathway in all BAV cases. 
Portrait of these data is, indeed, the significantly decreased gene expression of inflammatory cytokines 
and TLR4, in both normal and aneurysmatic tissue samples, from BAV with AAA than TAV with AAA. In 
conclusion, our study demonstrates that subjects with BAV display a significant deregulation of TLR4 
signaling pathway paralleled by a deregulation of Notch-1 pathway, as previously showed. This data 
suggests that the crosstalk between the Notch-1 and TLR4 signaling pathways may play a crucial role 
in both physiological embryological development, and homeostasis and functionality of aortic valve in 
adult life.
A novel evidence sustains that the Toll-like receptor-4 (TLR4) signaling pathway has the role of hub in preserv-
ing aorta homeostasis, but also in contributing to the onset of degenerative aorta diseases, such as aneurysms1. 
Consistent with this, it is emerging the key role of TLR4 signaling pathway in the complex pathophysiology of 
sporadic ascending aortic aneurysms (AAA)1. Accordingly, we recently postulated the model of the signaling path-
way from the double-face1, supported by results of the recent investigations performed by our and other groups2–9. 
Specifically, it proposes that AAA is the result of a sustained/excessive activation of TLR4 signaling pathway, 
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expressed on both endothelial and vascular smooth muscle cells, followed by its cross-talk with other pathways, 
including the Notch pathway, but also by TGF-β, NO, MMP, NF-Kβ pathways1,8.
Here, we investigated if TLR4 signaling pathway is involved as one of the main determinants of both patho-
physiology and early onset of AAA in patients affected by bicuspid aortic valve (BAV). BAV is the most common 
congenital cardiac malformation, affecting approximately 1.3% of the population worldwide10–12 with AAA and 
dissection representing its common complications, even if the related mechanisms are not completely known10–12. 
We recently evidenced the presence of distinctive molecular and cellular mechanisms in BAV patients, when 
compared to tricuspid aortic valve (TAV) patients with or without AAA11–13. Specifically, we demonstrated an 
increased allele frequency of some polymorphisms in genes encoding molecules of NO, MMP, ACE pathways13, 
a quantitative reduction in the circulating levels of T and B lymphocytes cell subsets14, a deregulation of Notch 1 
pathway and circulating endothelial progenitor cell (EPC)15 number in BAV cases compared to TAV cases, irre-
spective from the presence of AAA disease.
TLR4 signaling pathway is known to modulate both the expression and function of the above-mentioned 
pathways1. A close crosstalk between TLR-4 and the abovementioned pathways has been proposed1,16, which 
seems to explain the multitude of TLR4 actions and its biological effects on the cardiovascular system, as well as 
in the aorta and aortic valve. Of crucial importance, is the crosstalk between TLR-4 and Notch pathways1,16. A 
growing evidence supports these observations, as reported in previous works1,16.
Thus, alterations in these pathways result in a deregulation of vascular homeostasis and valvulogenesis, fol-
lowed by both valve and vascular structure abnormalities and the onset of pathological conditions, such as valve 
degeneration, endothelial dysfunction, medial degeneration and vascular degeneration, significantly associated 
with the development and progression of AAA. Accordingly, we hypothesized that a deregulation of TLR-4 path-
way could be related to BAV disease, thereby contributing to AAA onset and progression. Consequently, the main 
aim was to evaluate TLR-4 signaling in a cohort of BAV and TAV patients, with or without AAA13.
Results
Systemic levels of TNF-α, IL-6, IL-1, IL-17 and s-TLR4. First, we tested blood levels of TNF-α, IL-1, 
IL-6 and IL-17 in plasma samples, since accumulating lines of evidence pointed out a crucial role of inflamma-
tion of the aortic wall in contributing to the development and progression of aortic aneurysm1,8,9,11,17–19. The 
comparisons, among the four groups, demonstrated that the systemic levels of these cytokines were lower in 
BAV subjects without AAA with respect to other groups (see Table 1). In BAV subjects with AAA, we observed a 
significant increase of systemic levels of these cytokines when compared to the levels of BAV cases without AAA. 
In contrast, TAV individuals showed higher significant levels of these cytokines independently of the presence or 
absence of AAA, when compared to BAV cases with or without AAA. The presence of AAA determined a rise of 
Systemic molecules 
examined
BAV without 
AAA N = 19
BAV with 
AAA N = 51 P*
TNF-α (pg/ml) 8.18 ± 1.9 28 ± 5.4 <0.0001
IL-6 (pg/ml) 20 ± 4.3 68 ± 5.6 <0.0001
IL-1 (pg/ml) 22 ± 1.4 55 ± 8 <0.0001
IL-17 (pg/ml) 16 ± 1.9 78 ± 6 <0.0001
s-TLR4 (ng/ml) 1.5 ± 1.8 8.5 ± 2.1 <0.0001
Systemic molecules 
examined
TAV without 
AAA N = 45
TAV with 
AAA N = 25 P
TNF-α (pg/ml) 12.7 ± 4.3 75 ± 5.3 <0.0001
IL-6 (pg/ml) 28 ± 9 90 ± 8 <0.0001
IL-1 (pg/ml) 29 ± 6.5 72.4 ± 6 <0.0001
IL-17 (pg/ml) 21 ± 1.9 98 ± 6 <0.0001
s-TLR4(ng/ml) 4.5 ± 1.5 18 ± 4 <0.0001
Systemic molecules 
examined
BAV without 
AAA N = 19
TAV without 
AAA N = 45 P
TNF-α (pg/ml) 8.18 ± 1.9 12.7 ± 4.3 0.01
IL-6 (pg/ml) 20 ± 4.3 28 ± 9 0.01
IL-1 (pg/ml) 22 ± 1.4 29 ± 6.5 0.01
IL-17 (pg/ml) 16 ± 1.9 21 ± 1.9 0.01
s-TLR4 (ng/ml) 1.5 ± 1.8 4.5 ± 1.5 0.01
Systemic molecules 
examined
BAV with 
AAA N = 51
TAV with 
AAA N = 25 P
TNF-α (pg/ml) 28 ± 5.4 75 ± 5.3 0.0001
IL-6 (pg/ml) 68 ± 5.6 90 ± 8 0.001
IL-1 (pg/ml) 55 ± 8 72.4 ± 6 0.001
IL-17 (pg/ml) 78 ± 6 98 ± 6 0.001
s-TLR4(ng/ml) 8.5 ± 2.1 18 ± 4 0.001
Table 1. Systemic levels of TNF-α, IL-1, IL-6, IL-17, and s-TLR4. Tumor necrosis factor (TNF)-α, Interleukin 
(IL)-1, IL-6, IL-17; soluble-Toll-like receptor (sTLR)4. *By unpaired t-test with Welch correction.
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inflammatory cytokines in BAV cases, but to a lesser extent than TAV individuals (see Table 1). Thus, a deregu-
lated immune response seems to occur in BAV cases.
We also assessed the systemic levels of soluble TLR4 (s-TLR4) in plasma samples of the four groups enrolled. 
Levels of s-TLR4 depict the presence or absence of a constitutive balance between activation and inhibition of 
TLR4 signaling pathway1,20–22, representing decoy receptors with inhibitor action. This allows the control of 
TLR4 physiological actions in the milieu of the aortic wall, that is important for the homeostasis of aortic tissue1. 
Interestingly, we found reduced levels of s-TLR4 in BAV cases with or without AAA in comparison to the two 
groups of TAV subjects (1.5 ± 1.8 and 8.5 ± 2.1 vs. 12.7 ± 4.3 and 75 ± 5.3(ng/ml), respectively). This data should 
seem to indicate a deregulation in the activity or in the expression of TLR4 signaling pathway in all BAV cases.
Expression levels of TLR4, IL-1β, IL-6, and IL-17 genes in aortic tissues from BAV and TAV 
patients. To validate the significant reduction of plasma levels of inflammatory cytokines and the soluble 
form of TLR4 in all BAV subjects, we also evaluated the expression levels of TLR4 and IL-1β, IL-6, IL-17 genes in 
aorta tissues harvested from patients with BAV and TAV affected by AAA undergoing surgery. Specifically, they 
were detected in normal (control samples) and aneurysm aortic portions harvested from patients undergoing 
elective surgical repair. As represented in Fig. 1, the comparison of the levels of TLR4 gene expression, among the 
four groups, revealed significant differences (p < 0.0001, by ANOVA test, Bonferroni corrected, or t test, Welch 
corrected).
Of note, we observed that the levels of TLR4 gene expression were significantly lower in both, normal and 
aneurysmatic aorta samples from BAV cases with or without AAA in comparison to TAV cases with or with-
out AAA (see Fig. 1). They increased in BAV aneurysmatic aorta samples, but they showed, significant reduced 
values, when compared to gene expression levels of TLR4 in aneurysmatic aorta tissue samples from TAV cases 
with AAA (see Fig. 1). Likewise, we detected similar data by comparing the expression levels of IL-1β, IL-6, IL-17 
genes in normal aorta and aortic aneurysmatic samples from BAV and TAV patients (see Fig. 2). Increased gene 
expression was observed in aneurysmatic samples from both BAV and TAV patients, with higher levels observed 
in TAV cases (p = 0.0001, by t test, Welch corrected). Of note, a lowest expression of these four (TLR4, IL-1β, IL-6, 
IL-17) genes was detected in in normal aortic tissue samples from BAV cases (see Figs. 1, 2).
Figure 1. Expression levels of gene encoding TLR4 (relative to GAPDH). The figure reports the gene expression 
levels of TLR4 in normal or aneurysmatic tissue samples from 51 BAV and 25 TAV cases with AAA. The 
comparison of data showed significant differences among the four groups with p < 0.0001, by ANOVA test, 
Bonferroni corrected. Significant also were the levels of TLR4 gene expression by comparing data in normal 
aorta tissues from BAV and TAV cases (p = 0.0001, by t test, Welch corrected), and between two levels in 
aneurymatic tissue samples from TAV and BAV groups with AAA (p = 0.0001, by t test, Welch corrected). 
However, the lowest levels were observed in normal aorta tissues from BAV with AAA, that confirmed their 
systemic levels of s-TLR4. The statistical significance was detected by using t test and ANOVA test, when 
appropriate.
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Discussion
Chronic inflammation is recognized to be involved in degenerative pathological conditions of both aorta and aortic 
valve1,8,9,17–19. The early degeneration of aortic valve, accompanied by several serious complications (i.e. AAA, the 
most common), usually occurs in case of bicuspid valve condition10–12. BAV, initially considered the result of a 
simple embryonic defect during the valvulogenesis, is today recognized to have a complex pathophysiology11,12,23 
and progression mediated by diverse evolutionary conserved pathways, such as Notch-1, as recently demon-
strated by our group10,11,15. Established evidence is also demonstrating the key role of inflammatory pathways, 
such as TLR4 signaling pathway, in the aortic valve pathologies, such as calcific aortic valve disease11,15. In aortic 
valve, TLR4 signaling pathway is expressed in both human aortic valve endothelial and interstitial cells24–27, and 
mediates its biological effects fundamentally via modulation of Notch-1 pathway28. Recently, we demonstrated 
and emphasized this concept and the crucial role of TLR-4 signaling pathway in the onset and progression of 
AAA1,8,15,16.
Consistent with these observations, in this study we aimed to evaluate the role of this pathway in BAV disease 
and its common complication, such as AAA. We found reduced levels of both gene and tissue expression of TLR4 
signaling pathway in BAV cases, independently of the presence or absence of AAA. Portrait of these data is the 
decreased gene expression of inflammatory cytokines, that we detected in aorta tissue samples from BAV cases 
in comparison to TAV cases. We also observed significant reduced systemic levels of these cytokines in plasma 
samples from BAV cases, and particularly in those without AAA.
Thus, a deregulated gene ad tissue expression of TLR4 signaling pathway seems to characterize BAV disease. 
This signature might also explain the reduced levels of the regulatory molecules, such as s-TLR4, detected in 
plasma samples from BAV cases in respect to TAV subjects. In addition, the concomitant deregulation of Notch-1 
pathways, previously observed in BAV cases15, might also justify the reduced numbers of circulating T and B 
subsets and EPC14,15. These two pathways are, indeed, known to play a crucial role in physiological haematopoie-
sis29,30, the physiological release and functionality of progenitors, such as EPC8,30,31, as well as in embryological 
organogenesis and valvulogenesis1,16,23,30,32.
For these reasons we support the concept of BAV as a syndrome11,12,23, with a complex pathophysiology, char-
acterized by the deregulation of TLR4 and Notch-1 pathways, that are known to be crucial for the physiological 
homeostasis and function of aortic valve endothelial (AVEC) and interstitial (AVIC) cells, as well as the aorta wall 
cells. Consequently, we propose that the altered function and expression of these two pathways, observed in BAV 
disease, result in a reduced functionality of AVEC, AVIC and aortic wall cells, with an increased susceptibility to 
senescence and chronic inflammation finally leading to a functional impairment8,9,16,33–35.
Study limitations. The principal limitation of the study relies on the fact that it is associative, and this could 
limit the identification of the true cause-effect relationship between TLR4 signaling pathway and BAV disease, 
Figure 2. Expression levels of genes encoding inflammatory cytokines. The figure reports the gene expression 
levels of IL-1β, IL-6 and IL-7 in normal or aneurysmatic tissue samples from 51 BAV and 25 TAV cases with 
AAA. The comparison of data of each cytokine gene detected significant differences among the four groups with 
p < 0.0001, by ANOVA test, Bonferroni corrected, and between normal and aneurysmatic aorta tissues from 
BAV and TAV cases (p = 0.0001, by t test, Welch corrected), with the lowest peaks in all the aorta tissues from 
BAV cases. The statistical significance was detected by using t test and ANOVA test, when appropriate.
5Scientific RepoRtS |         (2019) 9:11028  | https://doi.org/10.1038/s41598-019-47412-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
and its complication AAA. Regarding this aspect, it should also consider that the TLR-4 function and expres-
sion are modulated not only by genetic variants and haplotypes1,9,36, but also by environmental factors (such as 
diet37, mite allergens and air pollution38), and their cross-interaction with microbiota37, which may remain in a 
healthy state or show alterations (i.e. dysbiosis and consequent endotoxemia associated with age or obesity)39 
and consequent epigenetic changes40. Current evidence is also demonstrating that  pharmacological treatments, 
such as antihypertension drugs (i.e. candesartan, an angiotensin type 1 receptor (AT1R) blocker) can inhibit the 
TLR4/Angiotensin II-induced NF-κB inflammatory signaling41. Thus, differences in the pharmacological ther-
apy administrated to various patients may represent another confounding factor. However, in our study, all the 
BAV and TAV patients were subjected to the same antihypertensive treatment. Furthermore, no investigations 
in this study were also performed for evaluating, whereas the reduced expression and function of TLR4 pathway 
correlated with a reduced grade of renewal and senescence of AVEC components of BAV valve than TAV valve. 
This might confirm the important data obtained in the previous study about the reduced circulating levels of 
EPC detected in BAV cases independently by the presence or not of an associated aortopathy. Lastly, another lim-
itation might be represented by the fact that age was lower in subjects with BAV thereby hypothetically interfering 
with the results even if this depends on the early onset of complications in BAV cases with respect to TAV cases.
Conclusions
In conclusion, our study demonstrates that subjects with BAV display a significant deregulation of TLR4 signaling 
pathway accompanied by a deregulation of Notch-1 pathway, as previously showed15. This data suggests that the 
crosstalk between the Notch-1 and TLR4 signaling pathways may play a crucial role in both physiological embry-
ological development, and homeostasis and functionality of aortic valve in adult life. Further investigations by 
means of new technologies, such as Cre/Lox recombination, might help to clear this aspect, as recently reported in 
literature42. The validation and confirmation of the relevance of these pathways may lead to use them as potential 
therapeutic targets for personalized treatments, until now inexistent for both BAV and AAA, and to identify a 
potentially suitable biomarker profile useful to facilitate management and outcome of this complex syndrome. 
Certainly, additional and larger studies, and the use of methodologies and technologies of new generation, such as 
the abovementioned Cre/Lox recombination42, are mandatory to validate and confirm these promising findings, 
as well as our suggestions.
In this context, investigations that clarify the effects of environmental triggers, such as diet, allergens, air 
pollution, drugs in the pathophysiology of BAV and AAA complication through activation of TLR-4 pathway, 
including the intriguing link between the intestinal microbiota and BAV mediated by the TLR4-pathway43, might 
also be helpful. Since everyone is the result of the sophisticated interplay between environmental factors and its 
genome, trascriptome, proteome, metabolome, microbiome, epigenome, exposome, we here suggest that it is nec-
essary to perform a more complex combination of investigations based on these aspects for obtaining interesting 
data in the study of BAV and AAA complication1,11,12.
Material and Methods
Study population. The population of 70 BAV subjects (50 males and 20 females; mean age: 58.8 ± 14.8 
years) and 70 TAV subjects (35 males and 35 females; mean age: 69.1 ± 12.8 years) with or without AAA, pre-
viously enrolled in the recent study from Balistreri and coworkers15, was also included in this investigation. 
Briefly, it was recruited from January 2015 to December 2016. The cases were randomly selected from patients 
referring to the Units of Cardiac Surgery (Department of Surgery and Oncology, University of Palermo) and 
Cardiology, for surgery replacement or routine care screening. Appropriate exclusion criteria were also used 
during the BAV/TAV enrollment, for the following diseases: a) cardiovascular diseases were excluded accord-
ing to history and by detecting apposite laboratory and imaging biomarkers as indicated by more recent ESC or 
ASC guidelines; b) connective tissue disorders were excluded by assessing markers of inflammation immuno-
logical (i.e. autoantibodies) and imaging biomarkers; c) inflammatory diseases (from infections to hematolog-
ical, gastrointestinal, urogenital, pulmonary, neurological, endocrinal inflammatory disorders, and neoplasies 
included) by detecting apposite laboratory (including complete blood cell count, erythrocyte sedimentation 
rate, glucose, urea nitrogen, creatinine, electrolytes, C reactive protein, liver function tests, iron, and proteins) 
and imaging biomarkers. In addition, all the cases enrolled belonged to the same ethnic group in Western 
Sicily. Thus, a very homogenous population was studied. Furthermore, elective or acute surgical treatment 
(using wheat operation, Bentall-De Bono and Tirone David surgical techniques, whenever possible) and com-
plementary tubular-ascending aorta resection were performed in the BAV and TAV patients with AAA after 
evaluation of aortic transverse diameter sizes by Computed Tomography scanning according to recent guide-
lines according to recent guidelines, as reported in our recent review9. Accordingly, an experienced physician 
evaluated aortic transverse diameter sizes by echocardiography (Philips Ie. 33) before either elective or urgent 
surgery. The dimension of the aortic annulus, sinuses of Valsalva, proximal ascending aorta (above 2.5 cm of 
the sino-tubular junction) and aortic arch were assessed pre-operatively by trans-thoracic echocardiography as 
well as in the operating theatre by trans-oesophageal-echocardiography before the institution of the cardiopul-
monary by-pass. These measures, together with demographic and clinical data (including comorbidities) were 
obtained from patients’ medical records and are presented in Table 2. In all BAV and TAV cases, hypertension 
was treated by beta-blockers.
Ethical Study Approval. Our study was performed in accordance with ethical standards of the Helsinki 
Declaration of the World Medical Association and Italian legislation, and it received approval from Regional 
Ethics Board in Palermo (No. APUNIP0094517)13 and all participants gave their informed consent. Data were 
encrypted to ensure patient s’ privacy. All clinical measurements were performed in blind.
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Quantifications of systemic levels of TNF-α, IL-6, IL-1, IL-17 and sTLR4. Venous blood samples 
were collected from all enrolled subjects in a fasting state (>8 h without food administration). In BAV and TAV 
cases, blood samples were collected within the first 3 h of their admission. Plasma samples were obtained after a 
centrifugation of 3500 rpm at 4 °C for 10 min immediately after collection and then stored at −80 °C for further 
analysis. Plasma TNF-α, IL-6, IL-1 IL-17 levels were measured by using ELISA technique and commercial kits 
(R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. Detection limits were 
0.7 pg/ml, 0.5 pg/ml, 1 pg/ml, 15 pg/ml for IL-6, TNF-α, IL-1, IL-17 respectively. All assays were run in duplicate. 
Regarding the quantification of blood sTLR4 concentrations, they were also measured by a commercial ELISA 
kits (USCN Life Science, Inc., Wuhan, China) with a lower limit of detection of 0.156 ng/ml.
Transcription analyses by using Real-time PCR (qRT-PCR). Full aortic segments with normal as well 
as aneurysmatic aortic wall from tubular-ascending aorta were collected from patients with AAA. Specimens 
were fixed in 10% neutral buffered formalin and then processed for routine paraffin embedding. Total RNA was 
extracted by using the Qiagen RNeasy FFPE kit, treated with DNase I enzyme (Promega) for 1 h at 37 °C and 
then cleaned by column purification (Qiagen). Total RNA concentration and quality were determined with a 
spectrophotometer. Then cDNA was prepared using 1–2 µg of RNA (Ready-To-Go, T-Primed First-Strand Kit, 
Amersham Bioscience). The synthesised cDNA was stored at -20 °C RT-PCR analysis. They were also succes-
sively utilized for evaluating the TLR4, IL-1β, IL-6 and IL-17 mRNA expression. In these analyses, we used the 
expression of a house-keeping gene, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as endogenous 
control for normalization of the amount of sample RNA. The reactions were also performed using SYBR Green 
(catalog no. QR0100 Sigma-Aldrich) qRT-PCR in a Light-Cycler (Roche). The sequences of TLR4, cytokines 
and GAPDH primers used were reported in Table 3. The results were analysed using the 2−ΔCt (Livak) relative 
expression method.
Variables BAV N = 70 TAV N = 70 P
Demographic characteristics
Age, mean (SD) 58.8 (14.8) 69.1(12.8) <0.0001
Male sex, No. (%)* 50 (71) 35(50) 0.009
Female sex, No. (%) 20 (29) 35 (50) 0.009
Body mass index, 
mean (SD) 26 (4.8) 26.3 (3.2) N.S.
Size and location of AAA
Subjects affected (%) 51 (73) 25(36) 0.00001
Size (mm), mean (SD) 53.3 (7.4) 50.3 (6.9) N.S.
Location, No:
Tubular ascending 
aorta 51 (100) 25 (100) N.S.
Comorbidity conditions, No (%)
CVD Family History 8 (11) 5 (7.1) N.S.
Smoking 26 (37) 20 (28) N.S.
Hypertension 55 (78) 50 (719 N.S.
Dyslipidemia 9 (13) 5 (7.1) N.S.
Diabetes mellitus 3 (4.2) 1 (1.4) N.S.
Renal failure 0 (0) 1 (1.4) N.S.
Dissection 0 (0) 0 (0) N.S.
Aortic valve pathology, No (%):
Normal 0 (0) 38 (54) 0.0001
Prolapse 8 (11) 0(0) 0.003
Vascular calcium 
fibrosis 35 (50) 7 (10) 2.4e-7
Atherosclerosis coronary syndrome, 
No (%): 2 (3) 1 (0.8) N.S.
Table 2. Demographic and clinical characteristics, comorbodity conditions, complications of 70 BAV and 
70 TAV subjects. *Percentage values on total BAV and TAV subjects. P = TAV vs. BAV, by t Student test for 
quantitative variables, or χ2 test for qualitative variables.
Human 
gene Forward Reverse
TLR-4 5′-AATCTAGAGCACTTGGACCTTTCC -3′ 5′-GGGTTCAGGGACAGGTCTAAAGA -3′
IL-1 β 5′-CTGTCCTGCGTGTTGAAAGA-3′ 5′-TTGGGTAATTTTTGGGATCTACA-3′
IL-6 5′-TCTCCACAAGCGCCTTCG-3′ 5′-CTCAGGGCTGAGATGCCG-3′
IL-17 5′-CTCATTGGTGTCACTGCTACTG-3′ 5′ CCTGGATTTCGTGGGATTGTG-3′
GAPDH 5′-GGTATCGTCGAAGGACTCATGAC-3′ 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′
Table 3. Primer sequences for qRT-PCR.
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Statistical analysis. Statistical analyses were performed using SPSS software version 20. Significant dif-
ferences among qualitative variables were calculated by using χ2 test. Continuous variables (including sys-
temic blood molecule, protein and gene expression levels) were expressed as mean ± SD (Standard deviation). 
Unpaired t-test (Welch corrected) was utilised to analyse the data between two groups, while one-way ANOVA or 
Kruskal-Wallis test followed by Bonferroni correction was applied to compare more than two groups. To identify 
possible correlations, a non-parametrical Spearman correlation test was also used. Differences were considered 
significant when a p value < 0.05 was obtained by comparison between the different groups.
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